Thomas Dick

Dick Thomas

Appointment(s)
  • Associate Professor, Department of Microbiology and Immunology
Administrative Appointment(s)
  • Director, Biosafety Level 3 Core Facility
Academic Qualifications
  • PhD, University of Heidelberg, Germany
Research Interest(s)
  • Tuberculosis
  • NTM
  • Antimicrobial Resistance
  • Drug Discovery
Recent Publications
  • 1. Wu ML, Tan J, Dick T. 2015 Dec. Eagle Effect in Nonreplicating Persister Mycobacteria. Antimicrob Agents Chemother. 59(12):7786-9. doi: 10.1128/AAC.01476-15. 26349831.
  • 2. Moreira W, Ngan GJ, Low JL, Poulsen A, Chia BC, Ang MJ, Yap A, Fulwood J, Lakshmanan U, Lim J, Khoo AY, Flotow H, Hill J, Raju RM, Rubin EJ, Dick T. 2015 May. Target mechanism-based whole-cell screening identifies bortezomib as an inhibitor of caseinolytic protease in mycobacteria. mBio. MBio.6(3):e00253-15. doi: 10.1128/mBio.00253-15. 25944857.
  • 3. Gopal P, Dick T. 2015 Apr. The new tuberculosis drug Perchlozone┬« shows cross-resistance with thiacetazone. Int J Antimicrob Agents. 45(4):430-3. doi: 10.1016/j.ijantimicag.2014.12.026. 25704063.
  • 4. Gengenbacher M, Dick T. 2015 Apr. Antibacterial drug discovery: doing it right. Int J Antimicrob Agents. 45(4):430-3. doi: 10.1016/j.chembiol.2014.12.005. 25615950.
  • 5. Kana BD, Karakousis PC, Parish T, Dick T. 2014 Dec. Future target-based drug discovery for tuberculosis?. Tuberculosis (Edinb). 94(6):551-6. doi: 10.1016/j.tube.2014.10.003. 25458615.